MIMETAS Elected Most Innovative Company of the Netherlands
November 02, 2022
LEIDEN, The Netherlands, November 02, 2022 / B3C newswire / -- MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners and market position.
Henk Volberda, chairman of the jury and professor of Strategy & Innovation at the University of Amsterdam: “MIMETAS is world-leading. Since its foundation in 2013, the company has grown considerably, with branches in Europe, the USA and Asia. It can now count the largest pharmaceutical companies worldwide among its partners. With its miniaturized organs-on-a-chip, MIMETAS has found a promising approach to enable major advancements in the pharmaceutical industry.”
“The whole MIMETAS team is extremely proud to receive this recognition with such a distinguished pedigree,” says Jos Joore, CEO of MIMETAS, “Being a global organization today, we greatly appreciate this recognition from the audience and jury in our home country. We believe the strong innovation backbone in the Netherlands has nurtured the radical innovation mindset of MIMETAS. This mindset is absolutely required to keep changing how we develop new therapies, address unsolved diseases and reduce animal testing.”
The Dutch Innovation Award is based on the Dutch Innovation Monitor. It is an initiative of the Amsterdam Center for Business Innovation of the University of Amsterdam that approached 25,000 people for this study. The winner of the prestigious Dutch Innovation Prize 2022 is the result of a nomination by an expert jury and the public vote. As the 2022 award winner, MIMETAS succeeds ASML, today’s global leader in semiconductor equipment and Europe’s largest high-tech company.
MIMETAS (Leiden, The Netherlands) is a global leader in human-relevant disease models for drug discovery and development. Based on its proprietary OrganoPlate® platform, MIMETAS has developed a broad spectrum of disease assays with unrivalled physiological comprehensiveness. The company deploys its disease models in partnerships with the global top-50 pharmaceutical industry to find and develop first-in-class targets and compounds. MIMETAS was founded in 2013 in Leiden, the Netherlands, and has grown into a multinational company with operations in Europe, Asia and the USA. To learn more about MIMETAS's disease modeling capabilities and its OrganoPlate® platform, please visit www.mimetas.com.
Jos Joore, CEO